63,050 Shares in Surmodics, Inc. $SRDX Acquired by Thompson Davis & CO. Inc.

Thompson Davis & CO. Inc. acquired a new stake in Surmodics, Inc. (NASDAQ:SRDX) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 63,050 shares of the company’s stock, valued at approximately $1,873,000. Surmodics comprises 0.8% of Thompson Davis & CO. Inc.’s holdings, making the stock its 12th biggest position. Thompson Davis & CO. Inc. owned approximately 0.44% of Surmodics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of the business. Principal Financial Group Inc. boosted its stake in Surmodics by 1.8% during the 1st quarter. Principal Financial Group Inc. now owns 36,699 shares of the company’s stock worth $1,120,000 after purchasing an additional 638 shares during the period. Geode Capital Management LLC raised its holdings in shares of Surmodics by 0.3% in the second quarter. Geode Capital Management LLC now owns 336,239 shares of the company’s stock valued at $9,992,000 after buying an additional 1,128 shares during the last quarter. Inspire Investing LLC boosted its stake in shares of Surmodics by 11.3% during the first quarter. Inspire Investing LLC now owns 11,250 shares of the company’s stock worth $343,000 after buying an additional 1,142 shares during the period. Murchinson Ltd. grew its holdings in shares of Surmodics by 5.8% during the first quarter. Murchinson Ltd. now owns 52,981 shares of the company’s stock worth $1,618,000 after buying an additional 2,900 shares during the last quarter. Finally, Strs Ohio acquired a new position in Surmodics in the 1st quarter valued at about $122,000. 96.63% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have weighed in on SRDX shares. Zacks Research raised Surmodics to a “hold” rating in a research report on Tuesday, August 12th. Barrington Research reiterated a “market perform” rating on shares of Surmodics in a research note on Monday, August 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Surmodics in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $43.00.

Surmodics Price Performance

Surmodics stock opened at $41.52 on Thursday. The company has a quick ratio of 3.10, a current ratio of 3.91 and a debt-to-equity ratio of 0.27. The firm’s 50-day simple moving average is $29.93 and its 200 day simple moving average is $30.91. Surmodics, Inc. has a 52 week low of $25.87 and a 52 week high of $41.67. The firm has a market capitalization of $593.65 million, a PE ratio of -33.79 and a beta of 1.30.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).